During the past decade, Galen Medical Group conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 2 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 2 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Galen Medical Group" are "Ulcerative Colitis" (2 trials), "Heartburn" (1 trials), "Non-Erosive Gastro-Esophageal Reflux Disease" (1 trials) and "Primary Sclerosing Cholangitis" (1 trials). Many other conditions were trialed in "Galen Medical Group" in a lesser frequency.

Most popular intervention types in "Galen Medical Group" are "Drug" (4 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "Mirikizumab" (1 trials), "Mirikizumab IV" (1 trials), "Mirikizumab SC" (1 trials) and "Placebo SC" (1 trials). Other intervention names were less common.

The vast majority of trials in "Galen Medical Group" are 4 trials for "All" genders.

Currently, there are NaN active trials in "Galen Medical Group". undefined are not yet recruiting, 2 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Galen Medical Group, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Galen Medical Group, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".